2型糖尿病药物研发

Search documents
Biomea Fusion rises after results from type 2 diabetes drug
Seeking Alpha· 2025-10-06 20:45
Biomea Fusion (NASDAQ:BMEA) shares rose after reporting positive results from its mid-stage study testing icovamenib in individuals with type 2 diabetes over a 52-week period. The stock closed up 24% on Monday. The study found that icovamenib provided lasting treatment ...